May 8, 2020 / 9:48 PM / 16 days ago

BRIEF-Merck Says FDA Approved Lynparza By As First-Line Maintenance Treatment With Bevacizumab For Ovarian Cancer

May 8 (Reuters) - Merck & Co Inc:

* LYNPARZA® (OLAPARIB) APPROVED BY FDA AS FIRST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB FOR HRD-POSITIVE ADVANCED OVARIAN CANCER

* MERCK - FDA HAS APPROVED LYNPARZA IN COMBINATION WITH BEVACIZUMAB AS A FIRST-LINE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED OVARIAN CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below